A
web-based Atlas of Patient-Derived Xenografts
of cancer patients:A resource of MURAL PDX data
Download csv
Download xlsx
This table displays an overview of the database
The table can be sorted by any field, simply by clicking on the column header
The table can be sorted by any field, simply by clicking on the column header
| PDX ID | Sample Site | Sample Source | Age Sample Collected | PSA at diagnosis (ng/mL) | Id | Sample ID | Current PDX Generation | Average PDX Generation Time (days ± SEM) | Tumor preparation2 | Pubmed ID | Created Date | Audit Date | Patient Id | Gleason Score | Primary Gleason Score | Secondary Gleason Score | Grade Group | Tumour Grade | D'Amico Risk Classification | Primary Tumour Volume (cc) | Treatment Prior to Specimen Collection | PDX Host Type | PDX Graft Site |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 426M | Lung | Surgery | 27 | NA | 22 | 426M | 6 | 83 ± 5 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 426/452 | — | — | — | — | — | — | 0.0 | PRRT LuTate and Y-Tate, Octreotide | Testosterone supplemented | Subcutaneous |
| 426M Cx | Lung | Surgery | 27 | NA | 23 | 426M | 9 (5*) | 138 ± 9 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 426/452 | — | — | — | — | — | — | 0.0 | PRRT LuTate and Y-Tate, Octreotide | Castrate | Subcutaneous |
| 452C | Prostate | Transurethral resection of the prostate | 28 | NA | 24 | 452C | 6 | 87 ± 11 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 426/452 | — | — | — | — | — | — | 0.0 | PRRT LuTate and Y-Tate, Octreotide | Testosterone supplemented | Subcutaneous |
| 27.1A | Brain | Autopsy | 72 | 42 | 25 | 27.1A | 24 | 84 ± 4 | Tumor solid | 34413304; 30049486 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 27 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone | Testosterone supplemented | Subcutaneous |
| 27.1A Cx | Brain | Autopsy | 72 | 42 | 26 | 27.1A | 29 (8*) | 82 ± 8 | Tumor solid | 34413304; 30049486 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 27 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone | Castrate | Subcutaneous |
| 27.2A | Inguinal lymph node | Autopsy | 72 | 42 | 27 | 27.2A | 31 | 53 ± 6 | Tumor solid | 34413304; 30049486 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 27 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone | Testosterone supplemented | Subcutaneous |
| 27.2A Cx | Inguinal lymph node | Autopsy | 72 | 42 | 28 | 27.2A | 23 (4*) | 81 ± 9 | Tumor solid | 34413304; 30049486 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 27 | — | — | — | — | — | — | 0.0 | ADT, docetaxel, abiraterone | Castrate | Subcutaneous |
| 197M | Spine | Surgery | — | 27.5 | 29 | 197M | 6 | 183 ± 20 | Tumor solid | 34413304 | 01/05/2022 11 a.m. | 13/05/2024 1 a.m. | 197/238 | — | — | — | — | — | — | 0.0 | Zoladex, ketoconazole, docetaxel, prednisolone, zoledronate, abiraterone, radiotherapy | Testosterone supplemented | Renal |